Jazz Pharmaceuticals plc Financials

Market Capitalization $6.62 Billion as of July 1, 2025

Valuations Metrics as of Jul. 4, 2025

Trailing PE	14.87
Forward PE	5.08
Price to Sales TTM	$1.63
Price to Book MRQ	$1.62
Enterprise to Revenue	2.31
Enterprise to EBITDA	6.74

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	11.86%
Operating Margin	-2.90%
Return on Assets TTM	3.99%
Return on Equity TTM	12.25%

Income Statement

Revenue TTM	$4,064,807,936
Revenue per Share TTM	$66.15
Quarterly Revenue Growth	-0.50%
Gross Profit TTM	$3,745,913,088
EBITDA	$1,256,088,000
Net Income to Common TTM	$482,196,992
Diluted EPS TTM	$7.36
Quarterly Earnings Growth YoY	-0.46%

Balance Sheet

Total Cash MRQ	$2,571,982,080
Total Cash per Share MRQ	$41.73
Total Debt MRQ	$
Total Debt to Equity MRQ	129.82
Current Ratio MRQ	3.38
Book Value per Share MRQ	$67.75

Cash Flow

Operating Cash Flow TTM	$1,558,462,976
Levered Free Cash Flow TTM	$1,495,155,328

JAZZ Stock Info as of Jul. 4, 2025

Stock Statistics

Shares Outstanding	60,631,000
Float Shares	59,666,753
Avg 10 Volume	720,160
Avg 30 Volume	None
Shares Short	5,828,993
Short Ratio	6.58
Short % of Shares	11.14%
% Held by Insiders	3.07%
% Held by Institutions	101.94%

Stock Price Summary

Beta	0.33
Fifty Two Week Low	$95.49
Fifty Two Week High	$148.06
Fifty Two Week Change	7.47%
Day 50 MA	$108.93
Day 200 MA	$118.23

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date